HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 243 filers reported holding HAEMONETICS CORP in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,568,027 | -8.9% | 151,463 | -13.4% | 0.66% | +0.9% |
| Q2 2023 | $14,886,729 | +3.1% | 174,850 | +0.2% | 0.65% | -5.9% |
| Q1 2023 | $14,438,137 | +4.2% | 174,479 | -1.0% | 0.69% | +3.3% |
| Q4 2022 | $13,856,085 | -41.7% | 176,174 | -45.2% | 0.67% | -45.4% |
| Q3 2022 | $23,784,000 | +13.6% | 321,271 | +0.0% | 1.23% | +14.0% |
| Q2 2022 | $20,935,000 | +23.8% | 321,182 | +20.0% | 1.08% | +66.8% |
| Q1 2022 | $16,914,000 | +115.0% | 267,548 | +204.6% | 0.64% | +88.0% |
| Q2 2020 | $7,867,000 | -71.2% | 87,835 | -68.0% | 0.34% | -78.3% |
| Q1 2020 | $27,322,000 | -4.3% | 274,150 | +10.3% | 1.58% | +31.0% |
| Q4 2019 | $28,555,000 | +11.2% | 248,520 | +22.0% | 1.21% | +0.5% |
| Q3 2019 | $25,687,000 | +17.8% | 203,640 | +12.4% | 1.20% | +37.0% |
| Q2 2019 | $21,802,000 | +59.0% | 181,170 | +15.6% | 0.88% | +57.0% |
| Q1 2019 | $13,713,000 | +6.6% | 156,760 | +21.9% | 0.56% | -11.8% |
| Q4 2018 | $12,867,000 | – | 128,607 | – | 0.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |